StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.70−0.05 (-6.48%)

Close on Nov 18, 2026Market cap $240.43MP/E –Yield 0.00%

Allogene Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Allogene Therapeutics's price to sales ratio was 14.7× on Jan 31, 2023, against 42.4× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Jan 31, 202314.7×+2.7
2022Dec 30, 202212.0×−43.3
2021Dec 31, 202155.3×–

More Allogene Therapeutics figures

See a number that looks wrong?